keyur patel
keyur patel
UHN Toronto
Verified email at
Cited by
Cited by
Treatment of HCV infection by targeting microRNA
HLA Janssen, HW Reesink, EJ Lawitz, S Zeuzem, M Rodriguez-Torres, ...
New England Journal of Medicine 368 (18), 1685-1694, 2013
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
IM Jacobson, SC Gordon, KV Kowdley, EM Yoshida, M Rodriguez-Torres, ...
New England journal of medicine 368 (20), 1867-1877, 2013
Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C
JG McHutchison, M Manns, K Patel, T Poynard, KL Lindsay, C Trepo, ...
Gastroenterology 123 (4), 1061-1069, 2002
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ...
The Lancet 394 (10215), 2184-2196, 2019
Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection
GR Foster, N Afdhal, SK Roberts, N Bräu, EJ Gane, S Pianko, E Lawitz, ...
New England Journal of Medicine 373 (27), 2608-2617, 2015
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus
AJ Thompson, AJ Muir, MS Sulkowski, D Ge, J Fellay, KV Shianna, ...
Gastroenterology 139 (1), 120-129. e18, 2010
Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients
K Patel, SC Gordon, I Jacobson, C Hézode, E Oh, KM Smith, ...
Journal of hepatology 41 (6), 935-942, 2004
The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients
HM Patton, K Patel, C Behling, D Bylund, LM Blatt, M Vallée, S Heaton, ...
Journal of hepatology 40 (3), 484-490, 2004
IL28B genotype is associated with differential expression of intrahepatic interferon‐stimulated genes in patients with chronic hepatitis C
TJ Urban, AJ Thompson, SS Bradrick, J Fellay, D Schuppan, KD Cronin, ...
Hepatology 52 (6), 1888-1896, 2010
Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin
JJ McCarthy, JH Li, A Thompson, S Suchindran, XQ Lao, K Patel, ...
Gastroenterology 138 (7), 2307-2314, 2010
A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice
HL Tillmann, AJ Thompson, K Patel, M Wiese, H Tenckhoff, HD Nischalke, ...
Gastroenterology 139 (5), 1586-1592. e1, 2010
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response
A Mangia, AJ Thompson, R Santoro, V Piazzolla, HL Tillmann, K Patel, ...
Gastroenterology 139 (3), 821-827. e1, 2010
Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication
M Bouvier‐Alias, K Patel, H Dahari, S Beaucourt, P Larderie, L Blatt, ...
Hepatology 36 (1), 211-218, 2002
Hepatitis B virus–specific and global T-cell dysfunction in chronic hepatitis B
JJ Park, DK Wong, AS Wahed, WM Lee, JJ Feld, N Terrault, M Khalili, ...
Gastroenterology 150 (3), 684-695. e5, 2016
Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study
NH Afdhal, BR Bacon, K Patel, EJ Lawitz, SC Gordon, DR Nelson, ...
Clinical gastroenterology and hepatology 13 (4), 772-779. e3, 2015
Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial
K Patel, SA Harrison, M Elkhashab, JF Trotter, R Herring, SE Rojter, ...
Hepatology 72 (1), 58-71, 2020
Risks of a range of alcohol intake on hepatitis C‐related fibrosis
A Monto, K Patel, A Bostrom, S Pianko, P Pockros, JG McHutchison, ...
Hepatology 39 (3), 826-834, 2004
Limitations of non-invasive tests for assessment of liver fibrosis
K Patel, G Sebastiani
JHEP Reports 2 (2), 100067, 2020
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction
AJ Thompson, J Fellay, K Patel, HL Tillmann, S Naggie, D Ge, TJ Urban, ...
Gastroenterology 139 (4), 1181-1189. e2, 2010
Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH
R Loomba, M Noureddin, KV Kowdley, A Kohli, A Sheikh, G Neff, ...
Hepatology 73 (2), 625-643, 2021
The system can't perform the operation now. Try again later.
Articles 1–20